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exemestane group, n = 54) or 5 years of exemestane 
(exemestane-only group, n = 54). CTCs were again as-
sessed after the first 2 years of endocrine treatment. In ad-
dition, safety data were compared between the 2 groups. 
Results: The 2 groups were well-balanced with regard to 
baseline characteristics. The CTC clearance rate after 
2 years was 89% in the exemestane-only group and 97% 
in the tamoxifen-exemestane group (exact Fisher test, 
p = 0.36). The safety profile showed good tolerability with 
few grade 3 or 4 adverse events in both groups. Conclu-
sion: The similar CTC clearance rate after 2 years of endo-
crine therapy with exemestane or tamoxifen, and the 
safety profiles obtained may indicate comparable efficacy 
and tolerability of both endocrine treatment regimens. 
However, these results have to be confirmed by final sur-
vival and safety analysis.
© 2018 S. Karger GmbH, Freiburg
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Summary
Background: Optimal choice and sequence of endocrine 
treatment following adjuvant chemotherapy in postmeno-
pausal early breast cancer patients are still under discus-
sion and treatment stratification factors are missing. Pa-
tients and Methods: Postmenopausal women with HER2-
negative, hormone receptor-positive tumors and persist-
ing circulating tumor cells (CTCs; assessed using the 
FDA-approved CellSearch® System, Janssen Diagnostics, 
LLC) after chemotherapy were randomized to 2 years of 
tamoxifen followed by 3 years of exemestane (tamoxifen-
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Introduction
For many years, treatment with the selective estrogen receptor 
(ER) modulator tamoxifen was a cornerstone of adjuvant therapy 
in postmenopausal patients with hormone receptor (HR)-positive 
breast cancer (BC). However, the development of aromatase in-
hibitors (AIs) that prevent the synthesis of estrogen from andro-
gens provided clinicians with a powerful alternative endocrine 
treatment option. There are 2 types of third generation AIs cur-
rently available for treatment of HR-positive BC. Type I AIs 
(exemestane) are steroidal permanent inhibitors, and type II AIs 
(anastrozole, letrozole) are non-steroidal reversible competitive in-
hibitors. Several trials have compared tamoxifen with AIs in the 
adjuvant treatment of HR-positive BC. A recent systematic review 
and meta-analysis revealed significantly improved disease-free sur-
vival (DFS) and overall survival (OS) for 5 years of AI treatment 
compared to 5 years of tamoxifen with high and moderate quality 
of evidence, respectively, albeit with rather small absolute differ-
ences [1]. In addition, the meta-analysis revealed a significant but 
small DFS benefit for the sequential tamoxifen-AI regimen com-
pared to tamoxifen monotherapy, but no significant difference in 
OS (though the difference approached significance) [1]. Alto-
gether, the evidence so far indicates that AIs (either as monother-
apy or following 2 years of tamoxifen) are superior to 5 years of ta-
moxifen monotherapy as endocrine treatment of postmenopausal 
BC patients, even if the gain in DFS is small and clear evidence re-
garding an OS benefit is still lacking [1–3]. However, it is still un-
known whether a sequential regimen (tamoxifen followed by AI or 
vice versa) or an AI monotherapy is to be preferred, as there is no 
convincing evidence suggesting significant differences with respect 
to both DFS and OS between these 2 treatment regimen [1]. Meta-
analyses of endocrine treatment-related adverse events showed 
that AIs were associated with a higher incidence of bone fractures, 
while tamoxifen was associated with a higher risk of endometrial 
cancer and venous thrombosis; in addition, sequential therapy with 
tamoxifen followed by AI was associated with a lower risk of devel-
oping cardiovascular disease compared to AI monotherapy [1, 4]. 
Thus, the decision between sequential treatment and AI monother-
apy may be based on the differences in the toxicity profile and pre-
existing risk factors.
Dissemination of circulating tumor cells (CTCs) from the pri-
mary tumor into the bloodstream is considered a risk factor and 
a critical step in tumorigenesis as CTCs are regarded a precursor 
of metastases by initiating tumor growth in distant organs [5, 6]. 
Several studies have revealed the independent prognostic value 
of CTCs assessed before the start of adjuvant chemotherapy in 
early BC (EBC) [7–10]. The independent prognostic relevance 
was also shown for the presence of CTCs after adjuvant chemo-
therapy [7, 11]. Recently, it was also demonstrated that persis-
tence of CTCs assessed during follow-up care 2 years after adju-
vant chemotherapy is associated with poor outcome in high-risk 
EBC patients [12].
The aim of this study is to present data regarding the compari-
son between a sequential endocrine treatment regimen (2 years ta-
moxifen followed by 3 years exemestane) and an AI monotherapy 
(5 years exemestane) in postmenopausal women with HER2-nega-
tive EBC and evidence of CTCs in the peripheral blood at the time 
of the last chemotherapy cycle (indicating increased risk of recur-
rence). This analysis represents the first results of the endocrine 
treatment sub-study of the randomized phase III German SUC-
CESS C trial, which compares anthracycline-containing and an-
thracycline-free chemotherapy in women with HER2-negative 
EBC. The endocrine treatment sub-study of SUCCESS C repre-
sents oneof the first clinical trials in which the presence of CTCs as 
a validated risk marker was used as an inclusion criterion for a sub-
sequent therapy randomization. We evaluated efficacy assessed 
based on the presence of CTCs and CTC clearance rate 2  years 
after the start of endocrine treatment as an early prognostic surro-
gate marker for clinical outcome. Thus, this first analysis evaluates 
efficacy after 2 years of tamoxifen versus 2 years of exemestane. In 
addition, we present the first data on safety in terms of the occur-
rence of adverse events during endocrine treatment. 
Patients and Methods
Study Design
SUCCESS C (NCT00847444) is a randomized multicenter open-label phase 
III clinical trial for women with histologically confirmed HER2-negative, high-
risk primary BC with an indication for adjuvant chemotherapy (either positive 
lymph nodes or high-risk node-negative BC, defined as tumor size larger than 
2 cm, histopathological grade 3, age ˯ 35 years or HR-negative primary tumor). 
The primary objectives of this study were to assess the efficacy of an anthra-
cycline-free adjuvant chemotherapy regimen in HER2-negative BC and to eval-
uate the effect of a lifestyle intervention program on DFS of EBC patients. A 
blood sample was collected immediately before the last chemotherapy applica-
tion for CTC assessment (see below) from all patients with HR-positive tumors 
who provided written informed consent for blood sampling as part of the trans-
lational research program of SUCCESS C. Determination of bone density be-
fore the start of therapy was not performed within the SUCCESS C study. Ac-
cording to the study protocol, bisphosphonates were not recommended, but the 
administration of bisphosphonates was admitted.
Postmenopausal HR-positive patients with evidence of CTCs in the periph-
eral blood at the time of the last chemotherapy cycle were eligible for the endo-
crine treatment sub-study. Given that they provided written informed consent 
for this sub-study, these patients were randomized to 5 years of treatment with 
the AI exemestane (25 mg p.o. per day; exemestane-only group) versus 2 years 
of tamoxifen (20 mg p.o. per day) followed by 3 years of exemestane (tamox-
ifen-exemestane group). Postmenopausal HR-positive patients without CTCs 
(and patients who did not provide written informed consent for the endocrine 
treatment sub-study) received exemestane (25 mg p.o. per day) for 5 years. Pa-
tients with HR-positive primary tumor under the age of 40 and/or with pre-
menopausal hormone levels (luteinizing hormone (LH) < 20 mlU/ml, follicle-
stimulating hormone (FSH) <  20  mlU/ml and estradiol (E2) >  20  pg/ml) re-
ceived goserelin (3.6 mg subcutaneously, every 4 weeks) for 2 years and tamox-
ifen (20  mg p.o. per day) for 5  years. The endocrine therapy schedule in 
SUCCESS C including the endocrine treatment sub-study is shown in Supple-
mental Fig. 1 (www.karger.com/?DOI=485566); the complete study design and 
more detailed information regarding trial concept, inclusion and exclusion cri-
teria, life-style intervention and translational research program is provided else-
where [13].
Patients
Overall, 3,642 patients were recruited to the SUCCESS C trial. Data on CTC 
prevalence at the date of last application of chemotherapy were available from 
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1,766 patients, and in 221 (12.5%) patients at least 1 CTC was detected. Out of 
136 CTC-positive patients with a postmenopausal status, 108 patients provided 
written informed consent and could be randomized for the endocrine treat-
ment sub-study (see Supplemental Fig.  2 (www.karger.com/?DOI=485566)). 
The study was conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice Guidelines, and was approved by all responsible ethic 
committees.
Tumor Characteristics and Safety Data
Tumor stages at primary diagnosis were classified according to the revised 
American Joint Committee on Cancer TNM classification system [14]. Histo-
logical grading was classified according to the Elston-Ellis modification of the 
Scarff-Bloom-Richardson grading system [15]. Tumors were defined as HR-
positive if the percentage of cells with immunohistochemical nuclear staining 
for estrogen and/or progesterone receptor was 10% or higher. HER2 negativity 
of the primary tumor was defined by negative immunohistochemistry (IHC) 
value of 0–1+ and/or negative fluorescent in situ hybridization.
Safety data were assessed according to the Common Terminology Criteria 
for Adverse Events of the National Cancer Institute, CTCAE Version 3.0. For 
the safety analyses reported here, all adverse and serious adverse events were 
included that occurred after randomization for the endocrine treatment sub-
study, which took place after the results of CTC assessment at the time of the 
last chemotherapy cycle were available (i.e. shortly before the start of endocrine 
treatment).
Detection of CTCs
As part of a SUCCESS C translational research sub-project, peripheral 
blood samples for CTC determination were collected from patients with HR-
positive tumors at the end of the systemic treatment (immediately before the 
last chemotherapy infusion or, in patients with early discontinuation of chemo-
therapy, 3 weeks after the last chemotherapy application). CTC analyses were 
performed using the FDA-approved CellSearch System® (Janssen Diagnostics, 
Raritan, USA) as described in detail elsewhere [16]. Samples with at least 1 de-
tected CTC were considered CTC positive.
Data Analysis
The analysis reported here is a non-preplanned interim analysis present-
ing first results of the endocrine treatment sub-study of the SUCCESS C trial. 
Data export for this analysis from the central data management database was 
conducted in April 2016. Data analysis is based on the intention-to-treat 
principle.
Adverse event term 
(CTCAE v3.0)
Exemestane-only group (n = 54) Tamoxifen-exemestane group 
(n = 54)
Grade 1 or 2 Grade 3 or 4 Grade 1 or 2 Grade 3 or 4
Leukopenia  6 (11.1), 13  6 (11.1), 6
Hypertension  3 (5.6), 3  7 (13.0), 8
Fatigue  5 (9.3), 5  6 (11.1), 11 1 (1.9), 1
Insomnia  5 (9.3), 6  5 (9.3), 6 1 (1.9), 1
Alopecia  5 (9.3), 6  4 (7.4), 5
Hot flushes  6 (11.1), 7  6 (11.1), 10 1 (1.9), 1
Hypercholesteremia 10 (18.5), 13  9 (16.7), 14
Creatinine  1 (1.9), 9  2 (3.7), 3
γ-Glutamyl transpeptidase  7 (13.0), 8  7 (13.0), 10
Hyperglycemia  9 (16.7), 12 11 (20.4), 15
Hypertriglyceridemia  5 (9.3), 7  6 (11.1), 10
Mood alteration: depression  6 (11.1), 7  3 (5.6), 3
Neuropathy: sensory  5 (9.3), 5 1 (1.9), 1  8 (14.8), 9
Bone pain  8 (14.8), 9 1 (1.9), 1  9 (16.7), 14 2 (3.7), 2
Joint pain 12 (22.2), 16  7 (13.0), 10
Table 1. Number of patients (%) affected by, and 
absolute frequencies of, the most common adverse 
events (Common Terminology Criteria for Adverse 
Events CTCAE v3.0) observed in the endocrine 
treatment sub-study of SUCCESSS C according to 
grade and randomization arm
Fig. 1. Frequency distribution of the number of circulating tumor cells 
(CTCs) detected according to randomization arm in postmenopausal patients 
with HER2-negative, hormone receptor-positive early breast cancer (EBC) pa-
tients randomized in the endocrine treatment sub-study of the SUCCESS C 
trial. A At the time of the last chemotherapy cycle (n = 108); B 2 years after ad-
juvant chemotherapy (n = 68).
A
B
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All categorical variables are described in terms of absolute and relative fre-
quencies, while the non-normally distributed continuous variables age and 
body mass index (BMI) as well as number of CTCs detected are described by 
reporting medians and ranges.
Associations between the presence of CTCs and patient as well as tumor 
characteristics were analyzed using the Mann-Whitney U-test for age and BMI, 
and the chi-square test for all categorical variables. Comparisons of adverse 
event frequencies between the 2 randomization arms (proportion of patients 
affected) were performed with chi-square tests (or Fisher’s exact test in case of 
expected frequencies of 5 or less in at least 1 cell of the 2 × 2 contingency ta-
bles). All statistical tests were 2-sided, and p values of less than 0.05 were con-
sidered significant (no adjustments of significance levels for multiple testing). 
Statistical analyses were performed using IBM SPSS Statistics, Version 21.0 s 
(IBM Corp., Armonk, New York, USA).
Results
CTC Prevalence and CTC Clearance Rates
Patient and tumor characteristics were well balanced between 
the 2 randomization arms of the endocrine treatment sub-study 
(see Supplemental Table 1 (www.karger.com/?DOI=485566)). CTC 
prevalence at the end of the systemic treatment was low even in the 
CTC-positive patient cohort eligible for this sub-study (median 2 
CTCs, range 1–12 CTCs), and there was no significant difference 
between the 2 randomization arms with regard to the number of 
CTCs detected (Mann-Whitney U-test, p = 0.30; fig. 1A). A CTC 
count 2 years after adjuvant chemotherapy was obtained for 68 pa-
tients (35 patients in the exemestane-only group, 33 patients in the 
tamoxifen-exemestane group). In the exemestane-only group, no 
CTCs were detected in 31 patients, while 1 CTC was detected in 3 
patients and 2 CTCs were detected in 1 patient; in the tamoxifen-
exemestane group, no CTCs were found in 32 patients and 1 pa-
tient had 2 CTCs (fig.  1B). Thus, the CTC clearance rates after 
2 years were 89% in the exemestane-only group and 97% in the ta-
moxifen-exemestane group, which was not significantly different 
(exact Fisher test, p = 0.36).
Safety
Overall, 585 adverse events were recorded in patients after they 
were randomized for the endocrine treatment sub-study. 283 ad-
verse events occurred in patients of the exemestane-only group 
(n = 54 patients) and 302 adverse events occurred in patients of the 
tamoxifen-exemestane group (n = 54 patients). In the exemestane-
only group, there were 207 (73.1%) grade 1, 63 (22.3%) grade 2, 11 
(3.9%) grade 3 and 2 (0.7%) grade 4 adverse events. Similarly, in 
the tamoxifen-exemestane group 217 (71.9%) grade 1, 68 (22.5%) 
grade 2, and 17 (5.6%) grade 3 adverse events occurred; no grade 4 
adverse event was observed. Supplemental Table  2 (www.karger.
com/?DOI=485566) shows numbers and percentages of patients af-
fected by adverse events according to category (CTCAE v3.0) as 
well as their absolute frequencies, grade and randomization arm. 
There were no significant differences between the 2 randomization 
arms with regard to the proportion of patients affected for any of 
the adverse event categories (all p > 0.05). The most common ad-
verse events with an overall absolute frequency of 10 or higher are 
listed in table  1; again, there were no significant differences be-
tween the 2 groups with regard to the proportion of patients af-
fected by these adverse events (all p > 0.15). 
In total, 52 adverse events (only grade 1 or 2) were regarded as 
being very likely associated with endocrine treatment (23 in the 
exemestane-only group, 29 in the tamoxifen-exemestane group). A 
likely association with endocrine treatment was stated for 55 ad-
verse events (30 in the exemestane-only group, 25 in the tamox-
ifen-exemestane group), all of which were grade 1 or 2 with the 
exception of one grade 3 bone pain event in the tamoxifen-exemes-
tane group. For 154 adverse events (74 in the exemestane-only 
group, 80 in the tamoxifen-exemestane group), association with 
endocrine treatment was rated as being possible. With the excep-
tion of 1 grade 3 bone pain event in the exemestane-only group, 
and 1 grade 3 fatigue and 1 grade 3 dizziness event in the tamox-
ifen-exemestane group, all these adverse events were grade 1 or 2 
only. The remaining 324 adverse events (including 24 grade 3 and 
2 grade 4 events) were categorized as not likely being associated 
with, or not being associated with, endocrine treatment. 
Discussion
Our preliminary efficacy analysis of the endocrine treatment 
sub-study of the SUCCESS C trial revealed no difference in CTC 
clearance rate between 2 years of endocrine treatment with either 
tamoxifen or exemestane in postmenopausal women with EBC 
who were at increased risk of recurrence (as assessed by the pres-
ence of CTCs at the time of the last chemotherapy cycle). The pre-
liminary safety analysis showed a comparable safety profile and 
good tolerability with only very few grade 3 or 4 adverse events in 
both the sequential endocrine regimen with 2 years of tamoxifen 
followed by 3 years of exemestane (tamoxifen-exemestane group) 
and the 5-year endocrine monotherapy with exemestane (exemes-
tane-only group).
A recent meta-analysis combining data from the 2 large rand-
omized trials comparing 5-year endocrine treatments with tamox-
ifen or AI (BIG-01-98, ATAC) revealed significantly improved 
DFS and OS for patients receiving AI monotherapy [1]. Our analy-
sis evaluating CTC prevalence after 2  years of tamoxifen versus 
2 years of exemestane treatment did not show a significant differ-
ence in CTC clearance rate between the 2 treatments. Since pres-
ence of CTCs 2 years after adjuvant chemotherapy is an independ-
ent prognostic factor for poor outcome in EBC patients [12], our 
results may indicate equal efficacy of both treatment regimen in a 
high-risk collective of HER2-negative BC patients, at least when as-
sessed 2 years after start of endocrine treatment. This result is in 
contrast to subgroup analyses of the BIG-01-98 trial, showing that 
the benefit for AI was most pronounced in high-risk (node-posi-
tive) patients, while the hazard ratios were not significant for node-
negative patients [17].
Two large trials investigated efficacy and safety of a sequential 
tamoxifen followed by AI regimen compared to 5 years of AI mon-
otherapy – similar to the design of the endocrine treatment sub-
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study of the SUCCESS C trial reported here – and thus provided 
suitable data for comparison. The BIG 01-98/IBCSG 18-98 trial 
(NCT00004205) compared 5 years of tamoxifen or letrozole mono-
therapy, or sequential treatment with 2 years of one of these drugs 
followed by 3 years of the other in postmenopausal women with 
HR-positive BC. The analysis regarding the comparison of 5 years 
of letrozole monotherapy with each of the 2 sequential regimen 
(tamoxifen followed by letrozole or vice versa) revealed no statisti-
cally significant differences with regard to DFS, OS, distant recur-
rence-free interval, or BC-free interval [17]. The TEAM (Tamox-
ifen Exemestane Adjuvant Multinational) trial (NCT00036270) 
compared 5  years of exemestane monotherapy and a sequential 
treatment regimen with 2.5–3.0  years of tamoxifen followed by 
exemestane for a total of 5 years in postmenopausal HR-positive 
BC. Similar to the results of BIG 01-98, no significant differences 
between the 2 arms with respect to DFS or OS were found [18]. 
Taken together, the results of both BIG 01-98 and TEAM suggest 
that a sequential 5-year endocrine treatment regimen with tamox-
ifen followed by an AI may be equally effective as 5-year AI mono-
therapy in postmenopausal primary BC patients.
The safety analysis of the BIG 01-98 trial and the TEAM trial 
provided comparable results regarding toxicity and tolerability of 
sequential treatments with tamoxifen followed by AI compared to 
AI monotherapy. While the sequential treatments with tamoxifen 
were associated with higher rates of thromboembolic events, gy-
necological symptoms (such as vaginal bleeding) and endometrial 
abnormalities (including endometrial cancer), AI monotherapy led 
to higher rates of musculoskeletal adverse events (in particular 
bone fractures), hypercholesterolemia or hyperlipidemia, and hy-
pertension [18, 19]. Similar results were obtained in a meta-analy-
sis evaluating toxicity of adjuvant endocrine therapy in postmeno-
pausal BC patients [4]. Our analysis indicated good tolerability 
with only very few grade 3 or 4 adverse events in both the tamox-
ifen-exemestane group and the exemestane-only group.
Several recent studies have confirmed the suitability of CTCs as 
assessed using the FDA-cleared CellSearch® System to serve as 
prognostic and/or predictive marker in EBC. The strong independ-
ent prognostic value of CTCs in the peripheral blood of BC pa-
tients before the start of adjuvant chemotherapy has been demon-
strated in a recent large pooled analysis of individual data from 
3,173 patients, showing that the presence of at least 1 CTC was sig-
nificantly associated with decreased OS, BC-specific survival, DFS, 
and distant DFS [10]. Presence of CTCs after adjuvant chemother-
apy is also associated with poor outcome [7, 11], and eligibility for 
the endocrine treatment sub-study was based on the presence of 
CTCs at the time of the last chemotherapy cycle as indicator of in-
creased risk of recurrence. While the individual CTC counts after 
adjuvant chemotherapy as found in our study appear to be rather 
low, they are similar to the CTC counts after chemotherapy in the 
2 studies that reported a significant association between the pres-
ence of at least 1 CTC after adjuvant chemotherapy and decreased 
DFS and/or OS [7, 11]. Thus, we are confident that the positive 
CTC count after adjuvant chemotherapy used as a marker for in-
creased risk of recurrence in our study indeed represents a mean-
ingful prognostic marker. Importantly, recent data provide strong 
evidence that the presence of CTCs 2 years after adjuvant chemo-
therapy is an independent prognostic factor for poor OS and DFS 
[12]. These data indicate that CTCs assessed 2 years after adjuvant 
chemotherapy may be used as easily accessible (by liquid biopsy) 
surveillance marker during routine long-term follow up of BC pa-
tients to guide risk-adapted tailored follow-up care. 
While the SUCCESS C endocrine treatment sub-study is novel 
because it is one of the first trials in which inclusion and randomiza-
tion to different therapies is contingent on the presence of CTCs as 
established risk factor for an increased risk of recurrence, there are 
also some limitations with regard to our first analysis of the endo-
crine treatment sub-study. Most obviously, the analysis is limited by 
the small number of patients that could be randomized for this 
study. In addition, it has to be noted that CTC prevalence after 
2 years only serves as an early available surrogate marker for out-
come. Furthermore, as CTC prevalence was determined 2 years after 
start of the endocrine treatment, this efficacy analysis compares 
2 years of tamoxifen and 2 years of exemestane (and thus does not 
represent a comparison between a 5-year sequential endocrine treat-
ment with tamoxifen followed by an AI and a 5-year AI monother-
apy as was the primary objective of the endocrine treatment sub-
study). Two years of endocrine treatment is rather short and repre-
sents not the standard of care in a high-risk population of BC pa-
tients such as those included in this endocrine treatment sub-study. 
Thus, both efficacy and safety data reported here have to be regarded 
as preliminary and as such have to be interpreted with care.
In conclusion, we could not find a significant difference be-
tween endocrine treatment with tamoxifen and exemestane with 
regard to CTC clearance rate 2 years after start of endocrine treat-
ment in postmenopausal HR-positive EBC patients with CTCs at 
the time of the last adjuvant chemotherapy cycle (indicating an in-
creased risk of recurrence). The safety profile obtained so far indi-
cated good tolerability in both the tamoxifen-exemestane group 
and the exemestane-only group. Our preliminary results thus sug-
gest comparable efficacy and tolerability of both endocrine treat-
ment regimen. However, final analyses of the endocrine treatment 
sub-study with regard to both survival and safety based on longer 
follow up data have to be awaited to be able to draw firm conclu-
sions regarding the efficacy and tolerability of a 5-year sequential 
endocrine treatment with tamoxifen followed by an AI as com-
pared to a 5-year AI monotherapy in postmenopausal EBC patients 
with an increased risk of recurrence.
Online Supplemental Material
Supplemental Table 1: Patient and tumor characteristics of postmen-
opausal patients with HER2-negative, hormone receptor-positive early breast 
cancer who had at least 1 CTC in the peripheral blood at the time of the last 
chemotherapy cycle and were randomized for the endocrine treatment sub-
study of the SUCCESS C clinical trial.
Supplemental Table 2 Number of patients (%) affected by and abso-
lute frequencies of adverse events observed in the endocrine treatment sub-
study of SUCCESSS C according to category (Common Terminology Criteria 
for Adverse Events (CTCAE) v3.0), grade and randomization arm.
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Supplemental Fig. 1. Endocrine therapy schedule and design of the 
endocrine treatment sub-study of the SUCCESS C clinical trial.
Supplemental Fig. 2. Flow chart of patient selection. CTC: Circulating 
tumor cell; HR: hormone receptor.
To access the online supplemental material, please refer to (www.karger.
com/?DOI=485566).
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